154 related articles for article (PubMed ID: 29805346)
1. Determination of the relationship between doxorubicin resistance and Wnt signaling pathway in HeLa and K562 cell lines.
Mutlu P; Yalçin Azarkan S; Taghavi Pourianazar N; Yücel M; Gündüz U
EXCLI J; 2018; 17():386-398. PubMed ID: 29805346
[TBL] [Abstract][Full Text] [Related]
2. Toxicity of doxorubicin-transferrin conjugate is connected to the modulation of Wnt/β-catenin pathway in human leukemia cells.
Szwed M; Kania KD; Jozwiak Z
Leuk Res; 2015 Oct; 39(10):1096-102. PubMed ID: 26271413
[TBL] [Abstract][Full Text] [Related]
3. Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia.
Corrêa S; Binato R; Du Rocher B; Castelo-Branco MT; Pizzatti L; Abdelhay E
BMC Cancer; 2012 Jul; 12():303. PubMed ID: 22823957
[TBL] [Abstract][Full Text] [Related]
4. Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells.
Zhong J; Zhang J; Yu X; Zhang X; Dian L
Med Sci Monit; 2020 Aug; 26():e924922. PubMed ID: 32830792
[TBL] [Abstract][Full Text] [Related]
5. Interference KRT17 reverses doxorubicin resistance in triple-negative breast cancer cells by Wnt/β-catenin signaling pathway.
Wu L; Ding W; Wang X; Li X; Yang J
Genes Genomics; 2023 Oct; 45(10):1329-1338. PubMed ID: 37634232
[TBL] [Abstract][Full Text] [Related]
6. [Down-Regulation of MiR-125b Reverses Drug Resistance of Doxorubicin-Resistant Leukemia Cells].
Deng YM; Luo AL; Li GF; Cai MS; Xu L; Yan MX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1610-1615. PubMed ID: 30501692
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells.
Chen Y; Zhao Y; Wang C; Xiao X; Zhou X; Xu G
Med Sci Monit; 2012 Oct; 18(10):BR383-8. PubMed ID: 23018344
[TBL] [Abstract][Full Text] [Related]
8. TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β‑catenin/TCF7/ABC transporter signaling axis.
Zhang H; Wang Y; Yang H; Huang Z; Wang X; Feng W
Oncol Rep; 2021 Feb; 45(2):557-568. PubMed ID: 33416164
[TBL] [Abstract][Full Text] [Related]
9. Flavonoids modulate multidrug resistance through wnt signaling in P-glycoprotein overexpressing cell lines.
Mohana S; Ganesan M; Rajendra Prasad N; Ananthakrishnan D; Velmurugan D
BMC Cancer; 2018 Nov; 18(1):1168. PubMed ID: 30477461
[TBL] [Abstract][Full Text] [Related]
10. Reversal of epithelial-mesenchymal transition and inhibition of tumor stemness of breast cancer cells through advanced combined chemotherapy.
Cui Y; Zhao M; Yang Y; Xu R; Tong L; Liang J; Zhang X; Sun Y; Fan Y
Acta Biomater; 2022 Oct; 152():380-392. PubMed ID: 36028199
[TBL] [Abstract][Full Text] [Related]
11. [Effect of Quercetin on Wnt/β-Catenin Signal Pathway of K562 and K562R Cells].
Li W; Zhao Y; Qiu L; Ma J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1409-1415. PubMed ID: 31607291
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
[TBL] [Abstract][Full Text] [Related]
13. [Small interfering RNA targeting STAT3 enhances antitumor activity of doxorubicin].
Wang TX; Wang YY; Zhang ZQ
Yao Xue Xue Bao; 2013 Jan; 48(1):52-8. PubMed ID: 23600141
[TBL] [Abstract][Full Text] [Related]
14. Restoration of WNT4 inhibits cell growth in leukemia-derived cell lines.
García-Castro B; Alvarez-Zavala M; Riveros-Magaña AR; Ortíz-Lazareno PC; Ratkovich-González S; Hernández-Flores G; Bravo-Cuellar A; Jave-Suarez LF; Aguilar-Lemarroy A
BMC Cancer; 2013 Nov; 13():557. PubMed ID: 24274766
[TBL] [Abstract][Full Text] [Related]
15. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.
Dieudonné FX; Marion A; Marie PJ; Modrowski D
J Bone Miner Res; 2012 Oct; 27(10):2118-29. PubMed ID: 22550000
[TBL] [Abstract][Full Text] [Related]
16. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of glutathione-related genes, enzyme activities and transport proteins in human cervical cancer cells treated with doxorubicin.
Drozd E; Krzysztoń-Russjan J; Marczewska J; Drozd J; Bubko I; Bielak M; Lubelska K; Wiktorska K; Chilmonczyk Z; Anuszewska E; Gruber-Bzura B
Biomed Pharmacother; 2016 Oct; 83():397-406. PubMed ID: 27424321
[TBL] [Abstract][Full Text] [Related]
18. Wnt pathway activity confers chemoresistance to cancer stem-like cells in a neuroblastoma cell line.
Vangipuram SD; Buck SA; Lyman WD
Tumour Biol; 2012 Dec; 33(6):2173-83. PubMed ID: 22886526
[TBL] [Abstract][Full Text] [Related]
19. The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression
Eadie LN; Saunders VA; Branford S; White DL; Hughes TP
Oncotarget; 2018 Mar; 9(17):13423-13437. PubMed ID: 29568367
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells.
Davies GF; Roesler WJ; Juurlink BH; Harkness TA
Leuk Lymphoma; 2005 Aug; 46(8):1199-206. PubMed ID: 16085563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
